The combination of CD24 and CD44 expression, such as CD24+/CD44+ and CD24-/CD44+, had been used to define CSCs in various other cancers, including breast, ovarian, prostate, pancreatic, colorectal, lung and renal cancer, but this had not yet been reported in HCC (131–142). Here, CD24 is linked to hepatocellular carcinoma.